COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ADDING TWICE-DAILY EXENATIDE TO INSULIN GLARGINE VERSUS ADING INSULIN LISPRO TO TREAT TYPE 2 DIABETES IN SPAIN

被引：0
|
作者：
Sanchez-Covisa, J. [1 ]
Capel, M. [1 ]
Baeten, S. [2 ]
Verheggen, B. G. [2 ]
机构：
[1] AstraZeneca, Madrid, Spain
[2] Pharmerit Int, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.723
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB101
引用
收藏
页码：A349 / A349
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ADDING TWICE-DAILY EXENATIDE TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SCOTLAND
    Varol, N.
    Wilson, B. P.
    Norrbacka, K.
    Valentine, W. J.
    Pollock, R. F.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [2] The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes
    Gordon, J.
    McEwan, P.
    Sabale, U.
    Kartman, B.
    Wolffenbuttel, B. H. R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1167 - 1174
  • [3] THE LONG-TERM COST-EFFECTIVENESS OF TWICE-DAILY EXENATIDE WITH INSULIN GLARGINE VERSUS ONCE-DAILY LIRAGLUTIDE WITH INSULINE DETEMIR IN ADULT PATIENTS WITH TYPE 2 DIABETES IN RUSSIA
    Krysanov, I
    Tiapkina, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [4] Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
    Braendle, M.
    Erny-Albrecht, K. M.
    Goodall, G.
    Spinas, G. A.
    Streit, P.
    Valentine, W. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (08) : 501 - 515
  • [5] Starting insulin for Type 2 diabetes with insulin glargine added to oral agents versus twice-daily premixed insulin alone
    Janka, HU
    Plewe, G
    Kliebe-Frisch, C
    Schweitzer, MA
    Yki-Järvinen, H
    [J]. DIABETOLOGIA, 2004, 47 : A269 - A270
  • [6] Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
    Eledrisi, Mohsen
    Suleiman, Noor Nabeel
    Salameh, Obada
    Hamad, Mohammad Khair
    Rabadi, Omar
    Mohamed, Ahmed
    Al Adawi, Rana
    Salam, Abdul
    [J]. JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2019, 15 : 35 - 36
  • [7] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [8] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [9] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [10] CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS: A MODELING ANALYSIS IN THE CHINESE SETTING
    Palmer, J. L.
    Beaudet, A.
    White, J.
    Plun-Favreau, J.
    Smith-Palmer, J.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A528 - A528
12345